This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cautions/contraindications

Authoring team

  • not licensed for children under the age of six years of age
  • also not licensed for children with hyperthyroidism; severe angina or cardiac arrhythmia; thyrotoxicosis; glaucoma; symptoms or family history of tics or Tourette's syndrome; agitation, anxiety or tension
  • this drug should be used with caution in children and young people with psychotic disorders, epilepsy, or a history of alcohol or drug dependence
  • adverse effects with stimulants are probably more common in pre-school children rather than older children and these drugs should be used with particular caution, if at all, in pre-school children (2)

Note that the manufacturer advises that Tourette's syndrome is a contraindication but these drugs (dexamphetamine, methylphenidate) can be valuable in the treatment of hyperactivity in such children (2).

The summary of product characteristics should be consulted before prescribing this drug.

Reference:

  • (1) NICE (October 2000). Guidance on the Use of Methylphenidate (Ritalin, Equasym) for Attention Deficit / Hyperactivity Disorder (ADHD) in childhood.
  • (2) Drug and Therapeutics Bulletin (2001), 39 (7), 52-54.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.